Shenzhen TargetRx is a high-tech pharmaceutical research and development company specializing in the creation of targeted drugs. Established in August 2014 as a Sino-American joint venture, the company received significant funding from prominent angel institutions in China, accumulating a registered capital of RMB 80 million. Founded by renowned medical expert Dr. Yihan Wang, who holds 27 authorized invention patents and has published over 60 papers, the company is focused on the development of small molecule targeted anti-cancer drugs. The recent Series A investment of $21.20M led by Shenzhen Capital Group, CCB International, Oriental Fortune Capital, and Tsing-Yuan Capital stands as a testament to the confidence in Shenzhen TargetRx's mission. With the objective of addressing acquired drug resistance and transforming cancer into a manageable chronic condition, the company is poised to make significant strides in the healthcare industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $21.20M | 4 |
|
04 May 2020 |
| Seed Round | $2.94M | 4 |
|
24 Jul 2018 |
No recent news or press coverage available for Shenzhen TargetRx.
We care about your data, and we'd love to use cookies make your experience better.
